SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) --
Caribou Biosciences, Inc. (NASDAQ: CRBU)
Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors.
If you are a current, long-term shareholder of Caribou Biosciences, Inc. you may have standing to hold Caribou Biosciences, Inc. harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.johnsonfistel.com/investigations/caribou-biosciences-inc
Recently a class action lawsuit was filed against the company. The complaint alleges that defendants made false statements and/or concealed that: (i) the treatment effect of the Company's product candidate, CB-010, was not as durable as defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated; and (iii) as a result, documents issued in connection with Caribou's initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Fate Therapeutics, Inc. (NASDAQ: FATE)
Johnson Fistel, LLP is investigating potential claims on behalf of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).
If you are a current, long-term shareholder of Fate Therapeutics holding shares before April 2, 2020, you can click or copy and paste the link below in a browser to join this action: https://www.johnsonfistel.com/investigations/fate-therapeutics-inc-2
Recently a class action lawsuit was filed against the company. The complaint alleges, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Globe Life Inc. (NYSE: GL)
Johnson Fistel, LLP is investigating potential claims on behalf of Globe Life Inc. (“Globe Life”) (NYSE: GL) against certain of its officers and directors.
If you are a current, long-term shareholder of Globe Life you may have standing to hold Globe Life harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action:
https://www.johnsonfistel.com/investigations/globe-life-inc
Recently, a civil lawsuit was filed by a former agent of American Income Life Insurance, Globe Life’s largest insurance subsidiary. The lawsuit against Simon Arias III, President of the Agency, and others alleges a pattern of unchecked sexual assault and harassment at the agency. The lawsuit describes a culture of abuse at a workplace that operated without guardrails. Johnson Fistel is investigating whether members of Globe Life’s board of directors or senior management failed to manage Globe Life in a satisfactory manner, in breach of their fiduciary duties, and whether Globe Life and its shareholders have suffered damages as a result.
Norfolk Southern Corporation (NYSE: NSC)
Johnson Fistel, LLP is investigating potential claims on behalf of Norfolk Southern Corporation (NYSE: NSC) against certain of its officers and directors.
If you have continuously owned Norfolk Southern shares before October 28, 2020, you can click or copy and paste the link below in a browser to join this action:
https://www.cognitoforms.com/JohnsonFistel/NorfolkSouthernCorporation2
During the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's PSR, including its use of longer, heavier trains staffed by fewer personnel, had led to the Company suffering increased train derailments and a materially increased risk of future derailments; (2) the Company's PSR, including its use of longer, heavier trains staffed by fewer personnel, was part of a culture of increased risk-taking at the expense of reasonable safety precautions due to the Company’s near-term focus solely on profits; (3) the Company's PSR, including its use of longer, heavier trains staffed by fewer personnel, rendered the Company more vulnerable to train derailments and train derailments with potentially more severe human, financial, legal, and environmental consequences; (4) the Company's capital spending and replacement programs were designed to prioritize profits over the Company’s ability to provide safe, efficient, and reliable rail transportation services; (5) the Company's lobbying efforts had undermined the Company’s ability to provide safe, efficient, and reliable rail transportation services; (6) the Company's commitment to reducing operating expenses as part of its PSR goals undermined worker safety and the Company’s purported “commitment to an injury free workplace” because the Company’s PSR plan prioritized reducing expenses through fewer personnel, longer trains, and less spending on safety training, technology, and equipment such as hot bearing wayside detectors (a/k/a “hotboxes”) and acoustic sensors; (7) the Company's rail services were, as a result of its adoption of PSR principles, more susceptible to accidents that could cause serious economic and bodily harm to the Company, the Company’s workers, the Company’s customers, third parties, and the environment; (8) the Company had failed to put in place responsive practices and procedures to minimize the threat to communities in the event that these communities suffered the derailment of a Norfolk Southern train carrying hazardous and toxic materials; and (9) as a result, defendants’ Class Period statements detailed above regarding the safety of Norfolk Southern’s operations were materially false and/or misleading.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: jimb@johnsonfistel.com
